TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Antisecretory Factor (AF) Effects on Intraocular-pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* open angle glaucoma, ocular hypertension~Exclusion Criteria:~* other types of glaucoma, other types of ocular comorbidity, previous intra-ocular surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo and Salovum (Type: EXPERIMENTAL): 6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
- Salovum and placebo (Type: EXPERIMENTAL): 6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Metabolic Changes Associated With Thalamic Stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-85 years old~* currently have DBS implanted for medically refractory epilepsy~* Women of childbearing age will be required to use established contraceptive methods while enrolled in the study.~Exclusion Criteria:~Patients who:~* are \< 18 years of age or \> 85 years of age~* are medically unstable~* are women who are potentially pregnant, pregnant or nursing~* have had PET imaging within 1 year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have histologically confirmed breast cancer~2. Hormone receptor positive or negative~3. Have assessable tumour by MRI or ultrasound~4. Are patients deemed unfit for surgical excision of tumour under general anaesthetic.~5. Have been given informed verbal and written consent for participation in the trial~6. Have stable hematologic, renal and hepatic functions.~Exclusion Criteria:~1. Are known to be HIV positive~2. Have active autoimmune disease~3. Are on corticosteroid medication~4. Have evidence of bleeding diathesis or coagulopathy.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- imILT (Type: EXPERIMENTAL): Immunostimulating Interstitial Laser Thermotherapy (imILT)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quantitative Genioglossal Muscle Strength in Obstructive Sleep Apnea (OSAS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 20-40 years inclusive BMI 18-25 Non-smoking history and no current use for a minimum of 6 months No smokeless tobacco products (including e-cigarettes) for a minimum of 6 months No sleep snoring reported by subject and by bedroom companion Self-described as active/athletic (i.e. regular hikes, walks, jogging, running, active Sports, such as volleyball, soccer, etc.) Self-described as healthy, with no known disease or recent illness Self-completed Epworth Sleepiness Scale of \<6 (Johns, MW, A new method for Measuring daytime sleepiness: the Epworth Sleepiness Scale; SLEEP 14:450-5, 1991). Physical Examination Mallampati Score of Class 1 (Nuckton, TJ, et al: Physical~Examination: Mallampati Score as an Independent Predictor of OSAS; SLEEP 29:~903-908, 2006).~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- OSAS subjects (Type: None): CPAP Referral OSAS
- Risk-Free subjects (Type: None): paired normal control subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A history of stage I-IIIB NSCLC~* Previously underdone definitive surgery or radiation~* Received prior adjuvant treatment or neoadjuvant with erlotinib or gefitinib for a total of at least 3 months at any time~* Stopped adjuvant erlotinib or neoadjuvant at least 2 months prior to date of first imaging demonstrating recurrence~* Pathologic evidence of recurrent lung cancer, confirmed at MSKCC EGFR sensitizing mutation (point mutation in exons 18 or 21, or deletion in exon 19) must be documented in the primary or recurrent tumor~* Tissue from their recurrent tumor must be submitted for EGFR mutation testing, and to evaluate for the presence of the T790M mutation (results do not need to have been reported to be eligible)~* Measurable disease by RECIST; if received prior irradiation, then must have a target lesion outside the irradiated field~* Signed informed consent~* Age \> or = to 21 years old~* Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 4 weeks after study drug is stopped~Exclusion Criteria:~* Prior progressive disease while receiving erlotinib or gefitinib therapy~* Patients with known pre-existing interstitial lung disease~* Total bilirubin greater than 1.8 mg/dl, excepting patients known to have Gilbert's syndrome~* AST or ALT greater than five times the upper limit of normal~* Pregnant or lactating women~* Medically unfit for erlotinib therapy as determined by treating oncologist

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- erlotinib (Type: EXPERIMENTAL): This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pain not controled by morphine~* Anxiety not controled by lorazepam~* Burn injuries of 20% or greater~* Burn type: scald or flame~Exclusion Criteria:~* Small burn injury~* Electrical burns

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female \> 18 years of age admitted to Surgical ICUs with suspected infection~* Calculated creatinine clearance \> 60ml/min~Exclusion Criteria:~* Age \< 18 years~* Allergic to vancomycin~* Calculated creatinine clearance \< 60ml/min~* Pregnant~* Vancomycin administration more than 8 hour and less than 24 hour prior to study enrollment~* Anticipated vancomycin treatment less than 2 days for surgical prophylaxis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin with continuous infusion (Type: EXPERIMENTAL): 24 hours continuous infusion
- Vancomycin with intermittent dose interval (Type: ACTIVE_COMPARATOR): infusion rate 1000mg/hr

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Endoscopy for Acute Upper Gastrointestinal Bleeding in Acute Coronary Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with recent (\< 2 weeks) ACS and acute upper GI bleeding accompanied with a decrease in hemoglobin (Hb) level greater than 2 g/dl~Exclusion Criteria (if any one of the following criteria is present):~* Malignancy or other advanced disease with a life expectancy of \< 6 months~* Pregnant or lactating women~* History of allergy or severe side effects to PPIs, contrast, and iodine~* Bleeding tendency, and platelet count \< 80k/uL, prothrombin time INR \>2.0~* Decompensated liver cirrhosis (Child-Pugh classification B\~C) and esophagogastric varices history~* Stage 3\~5 CKD (estimated Ccr \< 60 ml/min/1.73m2) using Cockcroft-Gault formula, exclusive of end-stage renal disease under renal replacement therapy~* Stigmata of hemorrhage confirmed as lower GI tract bleeders~* Without informed consents

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- early endoscopy (Type: EXPERIMENTAL): endoscopic hemostasis
- without early endoscopy (Type: NO_INTERVENTION): Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Data Registry for Outcomes From Surgical Treatment of Atrial Arrhythmias

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with paroxysmal (intermittent) or persistent atrial fibrillation~2. \> 18 years of age~Exclusion Criteria:~1. Patients unable to give adequate informed consent~2. Patients who are known to be pregnant, plan to become pregnant or are lactating~3. Inability to return for follow up~4. Patients who are prison inmates or institutionalized~5. Patients in an emergency state~6. Patients under the age of 18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Emotions and Coping Behaviour in Patients With Chronic Recurrent Low Back Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic low back pain \> 3 months~* VAS \>= 2~* understanding of german language~Exclusion Criteria:~* retired~* psychiatric disorders~* dementia~* sick headache~* chronic pain disease other than chronic low back pain~* patients with general contraindications of the therapy

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- outpatient rehabilitation program (Type: EXPERIMENTAL): whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
- physical therapy (Type: ACTIVE_COMPARATOR): prescribed physical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* high risk for HIT based on Four Ts score of 6 or more~Exclusion Criteria:~* pulmonary emboli at the time of enrollment~* arterial thrombosis at the time of enrollment~* limb threatening phlegmasia cerulea dolens at the time of enrollment~* Calculated Creatinin Clearance less than 50 ml/hr~* platelet count less than 50~* Weight less than 50 kg~* pregnancy~* allergy to fondaparinux~* bacterial endocarditis~* history of neuraxial anesthesia and post-operative indwelling epidural catheter~* active major bleeding (hemodynamically significant or requiring transfusions)~* inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fondaparinux (Type: EXPERIMENTAL): daily subcutaneous injection of fondaparinux (7.5-10 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial Comparing EmbryoScope With EmbryoScope+.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 40 years of age or younger (maternal)~* 65 years of age or younger (paternal)~* Fresh or frozen (including donor) sperm can be used~* Fresh oocytes only (including donor)~* Frozen embryos from this study can be included in the outcome portion of this study.~* Single or double Blastocyst transfer only~Exclusion Criteria:~* 3 or more previous failed cycles~* Sperm obtained by testicular biopsy~* Co-culture patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EmbryoScope (Type: ACTIVE_COMPARATOR): Standard of care embryo incubator.
- EmbryoScope+ (Type: EXPERIMENTAL): New experimental embryo incubator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with high risk hematological malignancies, including those with induction failure and after treated or untreated relapse. High risk hematological malignancies include: Acute myelogenous or lymphocytic leukemia with induction failure of after relapse, myelodysplastic syndrome of intermediate and high risk according to Greenberg criteria, chronic myelogenous leukemia in accelerated phase or blast crisis, non-Hodgkin's and Hodgkin's lymphoma with induction failure or relapse after chemotherapy and refractory or relapsed chronic lymphocytic leukemia.~2. HLA-identical sibling or matched unrelated donor transplants not eligible for protocols of higher priority.~3. Age 18-75 years.~4. Bilirubin \</=1.5 mg/dl, serum glutamic-pyruvic transaminase (SGPT) \</= 200 IU/ml.~5. Creatinine \</=1.6 mg/dl.~Exclusion Criteria:~1. Regimens including rituximab or alemtuzumab in the preparative regimen.~2. Patients can not have received prior treatment with gemtuzumab.~3. Planned conditioning chemotherapy for transplant can not include gemtuzumab.~4. Planned conditioning chemotherapy for transplant can not include the busulfan and cyclophosphamide regimen.~5. HIV seropositivity~6. Uncontrolled infection, not responding to adequate antimicrobial therapy after 7 days of treatment. The protocol PI is the final arbiter of eligibility.~7. Pregnancy~8. Inability to sign consent.~9. Patients who are past recipients of allogeneic or autologous stem cell transplants from any source.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Thymoglobulin + Sirolimus + MMF (Type: EXPERIMENTAL): Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Can You Reduce Problematic Smartphone Use Through a Group Intervention: A Single Case Experimental Design

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Self-identifies as struggling with problematic smart phone use~Exclusion Criteria:~* Actively experiencing suicidal or self-injurious thoughts, or have experienced these within the past year~* Already in a psychological therapy/intervention~* Planning a change of psychotropic medication during the research project.~* No access to video calling and/or slow internet connection speed~* A mental health condition that is not currently well managed/stable and therefore other interventions are likely to be more appropriate~* Does not own a smartphone that can record screen time~* Is not living in the UK, with access to services within the UK

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Problematic smart phone use course (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Remote Monitoring and Integrated Educational Program in OSA Patients Initiating Continuous Positive Airway Pressure (CPAP): (SLEEPCONNECT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Obstructive sleep apnea syndrome not treated with CPAP and defined by an apnea-hypopnea index (AHI) greater than 15 events per hour and with more than 80% of obstructive events, determined by polysomnography (PSG) or polygraphy (PG) within the last 6 months~* Treated hypertension or newly diagnosed hypertension defined as 140 ≤ SBP \<180 mmHg and 90 ≤ DBP\<110 mmHg~* BMI \> 28 kg / m²~* Smartphone~* Able to use a mobile application on a personal smartphone~* Medical certificate for the practice of physical activity/exercise~* Patients who have freely given their informed written consent~* Person affiliated to the French social security system~Exclusion Criteria:~* Central sleep apnea syndrome~* Patient with planned bariatric surgery~* Severe bullous emphysema~* Pneumothorax~* Trauma or recent surgery to or affecting the forebrain with sequelae of cranio-naso/pharyngeal fistula~* Decompensated cardiac insufficiency or hypotension, particularly in the event of reduced blood volume or in the case of cardiac arrhythmias~* Dehydration~* Tracheotomy~* Pregnant or lactating women~* Patient currently participating or having participated in the month prior to inclusion in another interventional clinical research project that may impact the study~* Patients under guardianship or curatorship~* Patients not affiliated to the French social security system or equivalent~* Patients deprived of their liberty or hospitalized without their consent~* Major patients protected by law~* Person under administrative or judicial review~* Minor patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CPAP S.Box associated with its 3 connected devices (Type: EXPERIMENTAL): S.BOXTM CPAP associated with its 3 connected devices Each patient will be monitored by a CPAP S.Box, with a Sefam Access application installed on their Smartphone to collect data from 3 connected measuring devices: PROMs, an activity monitor and a blood pressure monitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues